Frequently Asked Questions for RFA-HL-12-003: NHLBI Translational Research Implementation Program (TRIP)


Questions for November 2010:

Q:What is the primary objective of the RFA?

A: The overall research objective of the two-staged NHLBI Translational Research Implementation Program (TRIP) is to test the efficacy of new therapeutic interventions for cardiovascular, lung, and blood diseases in clinical trials. This specific funding opportunity announcement solicits Stage 2 applications for the conduct of clinical trials planned and developed during successful Stage 1 studies.

Q: Who is eligible to apply and when is the application deadline?

A: This is a limited competition open only to previously awarded Stage 1 planning studies, funded either as RC2 (TRIP) or P20 (C-TRIP) awards.

See the charts below for a list of eligible applicants and their deadlines.

Eligible RC2 Applications

Award Deadline: January 14, 2011

Eligible Applicants/Projects:

Grant # Title PI Name (Contact) Institution NHLBI Project Officer (PO) Name PO Phone PO email
1 RC2 HL101367-01 CTRIP: Treatment of Sickle Cell Crisis with inhibitors of NKT cell activation NATHAN, DAVID G. DANA-FARBER CANCER INSTITUTE LUKSENBURG, HARVEY (301) 451-6766 luksenburgh@mail.nih.gov
1 RC2 HL101641-01 CTRIP Ex-vivo perfusion and ventilation of lungs to assess transplant suitability EGAN, THOMAS M. UNIVERSITY OF NORTH CAROLINA CHAPEL HILL REYNOLDS, HERBERT Y (301) 435-0218 reynoldh@nhlbi.nih.gov
1 RC2 HL101740-01 CTRIP: Molecular phenotypes of rapidly progressive idiopathic pulmonary fibrosis MARTINEZ, FERNANDO J UNIVERSITY OF MICHIGAN AT ANN ARBOR REYNOLDS, HERBERT Y (301) 435-0218 reynoldh@nhlbi.nih.gov
1 RC2 HL101783-01 CTRIP: MMP1-PAR1-based Interventions in Arterial Thrombosis KULIOPULOS, ATHAN TUFTS MEDICAL CENTER KINDZELSKI, ANDREI L. (301) 402-0658 kindzelskial@nhlbi.nih.gov
1 RC2 HL101844-01 CTRIP:Notch-Mediated Expansion of Cord Blood Progenitors for Cord Blood Transplant DELANEY, COLLEEN FRED HUTCHINSON CANCER RESEARCH CENTER MONDORO, TRACI (301) 435-0075 mondorot@nhlbi.nih.gov
1 RC2 HL102222-01 CTRIP: Genetic Testing to Individualize Management of Common Heart Diseases DORN, GERALD W. WASHINGTON UNIVERSITY ADHIKARI, BISHOW B. (301) 435-0513 adhikarb@mail.nih.gov



Eligible P20 Applications

Award Deadline: April 4, 2011

Eligible Applicants/Projects:

Grant # Title PI Name (Contact) Institution NHLBI Project Officer (PO) Name PO Phone PO email
1 P20 HL100396-01 C-TRIP: Targeted Gene Therapy for the Treatment of Heart Failure (P20) HAJJAR, ROGER JOSEPH MOUNT SINAI SCHOOL OF MEDICINE OF NYU ADHIKARI, BISHOW B. (301) 435-0513 adhikarb@mail.nih.gov
1 P20 HL101397-01 PRIMARY ECG - MRI RISK STRATIFICATION LIMA, JOAO A C JOHNS HOPKINS UNIVERSITY DESVIGNE-NICKENS, PATRICE (301) 435-0515 desvignp@nhlbi.nih.gov
1 P20 HL101408-01 Using Genetics for Early Phenotyping & Prevention of Hypertrophic Cardiomyopathy HO, CAROLYN Y BRIGHAM AND WOMEN'S HOSPITAL KALTMAN, JONATHAN R (301) 435-0528 kaltmanj@mail.nih.gov
1 P20 HL101420-01 AC5 Inhibitor Treatment for Heart Failure VATNER, STEPHEN F UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL SCHWARTZ, LISA (301) 402-4826 schwartzlongal@mail.nih.gov
1 P20 HL101425-01 Recombinant Neuregulin for the treatment of Heart Failure SAWYER, DOUGLAS B VANDERBILT UNIVERSITY SCHWARTZ, LISA (301) 402-4826 schwartzlongal@mail.nih.gov
1 P20 HL101434-01 Docosahexaenoic Acid for Treatment of Heart Failure STANLEY, WILLIAM C UNIVERSITY OF MARYLAND BALTIMORE LIANG, ISABELLA Y (301) 435-0504 liangi@nhlbi.nih.gov
1 P20 HL101435-01 Using Molecular Pathology to Predict Response in Heart Failure LOWES, BRIAN D UNIVERSITY OF COLORADO DENVER SOPKO, GEORGE (301) 435-0515 sopkog@nhlbi.nih.gov
1 P20 HL101438-01 Combined Stem Cell and Assist Device Therapy for Heart Failure GREGORIC, IGOR TEXAS HEART INSTITUTE LIANG, ISABELLA Y (301) 435-0504 liangi@nhlbi.nih.gov
1 P20 HL101439-01 Protein Therapeutics to Prevent Heart Failure Post Myocardial Infarction BURNETT, JOHN C MAYO CLINIC SOPKO, GEORGE (301) 435-0515 sopkog@nhlbi.nih.gov
1 P20 HL101443-01 Autologous Adult Myocardial Cardioblasts to Treat Ischemic Heart Failure HARE, JOSHUA M UNIVERSITY OF MIAMI SCHOOL OF MEDICINE ADHIKARI, BISHOW B. (301) 435-0513 adhikarb@mail.nih.gov
1 P20 HL101820-01 TGA-ethanol Pretreated Bovine Pericardium for the Norwood Procedure LEVY, ROBERT J CHILDRENS HOSPITAL OF PHILADELPHIA KALTMAN, JONATHAN R (301) 435-0528 kaltmanj@mail.nih.gov
1 P20 HL101866-01 Cardiac progenitor cell therapy for advanced ischemic cardiomyopathy. PFEFFER, MARC A BRIGHAM AND WOMEN'S HOSPITAL DESVIGNE-NICKENS, PATRICE (301) 435-0515 desvignp@nhlbi.nih.gov

Q: Why are there two application deadlines?

A: Applications are due January 14, 2011 for eligible RC2 recipients and April 4, 2011 for eligible P20 recipients to allow each recipient group sufficient time to formulate their applications. All applications will be reviewed on one date by the same review group.

Q: Can any study from a Stage 1 TRIP/C-TRIP institution submit a Stage 2 application?

A: No, only awarded Stage 1 studies (listed above) are eligible to apply.

Q: Is separate funding available for the RC2 and P20 recipients?

A: No, all applicants will compete for the same Stage 2 funding regardless of whether their Stage 1 award was a RC2 or P20.


NHLBI Contact

David Lathrop, PhD
Division of Cardiovascular Sciences
dal@nih.gov

Last update: December 28, 2010

Skip footer links and go to content
Twitter iconTwitterExternal link Disclaimer         Facebook iconFacebookimage of external link icon         YouTube iconYouTubeimage of external link icon         Google+ iconGoogle+image of external link icon